In vivo and in vitro characterization of CYP2E1 activity in Japanese and Caucasians

RB Kim, H Yamazaki, K Chiba, D O'Shea, M Mimura, FP Guengerich, T Ishizaki, T Shimada and GR Wilkinson

Department of Pharmacology, Vanderbilt University, Nashville, Tennessee, USA.

Chlorzoxazone's disposition after oral administration was determined in 20 young healthy Caucasian men and a similar group of Japanese men. The drug's plasma concentrations were significantly higher and its rate of elimination slower in Japanese compared to Caucasian men. Accordingly, chlorzoxazone's oral clearance was smaller (40%) in Japanese men and a similar difference (30%) was still apparent after normalizing for body weight (3.74 +/- 1.23 versus 5.05 +/- 1.41 ml.min-1.kg-1, P < .05). This slower elimination was associated with a reduced (fractional) clearance by 6-hydroxylation (2.34 +/- 1.04 ml.min-1.kg-1 versus 3.23 +/- 1.10, P < .05). Because such metabolism is mediated by cytochrome P4502E1 (CYP2E1), these findings suggest a lower level of the enzyme's catalytic activity in Japanese men. This was confirmed by in vitro studies with microsomes prepared from livers of individuals representative of the two racial groups. CYP2E1 levels were lower (61% P < .002) and CYP2E1-mediated chlorzoxazone 6-hydroxylase (22%, P < .001) and aniline 4-hydroylase (35%, P < .0001) activities were reduced in Japanese preparations compared to those from Caucasians. No relationships were found between measures of CYP2E1 activity, both in vivo and in vitro, and genomic polymorphisms in the CYP2E1 gene identified by Rsal/Pstl and Dral restriction fragment length polymorphisms. Collectively, these data show an interracial difference in CYP2E1 activity. Because this enzyme is importantly involved in the activation of environmental procarcinogens, such a difference may account, in part, for the lower rate of some cancers, e.g., lung cancer, in Japanese compared to Caucasians men.

Volume 279, Issue 1, pp. 4-11, 10/01/1996
Copyright © 1996 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				M. Morita, S. Tabata, O. Tajima, G. Yin, H. Abe, and S. Kono Genetic Polymorphisms of CYP2E1 and Risk of Colorectal Adenomas in the Self Defense Forces Health Study Cancer Epidemiol. Biomarkers Prev., July 1, 2008; 17(7): 1800 - 1807. [Abstract] [Full Text] [PDF]

				J.-Y. Park, K.-A. Kim, P.-W. Park, and J.-M. Ha Effect of High-Dose Aspirin on CYP2E1 Activity in Healthy Subjects Measured Using Chlorzoxazone as a Probe J. Clin. Pharmacol., January 1, 2006; 46(1): 109 - 114. [Abstract] [Full Text] [PDF]

				F. P. Guengerich Cytochromes P450, Drugs, and Diseases Mol. Interv., June 1, 2003; 3(4): 194 - 204. [Abstract] [Full Text] [PDF]

				C. Gao, T. Takezaki, J. Wu, Z. Li, J. Wang, J. Ding, Y. Liu, X. Hu, T. Xu, K. Tajima, et al. Interaction between Cytochrome P-450 2E1 Polymorphisms and Environmental Factors with Risk of Esophageal and Stomach Cancers in Chinese Cancer Epidemiol. Biomarkers Prev., January 1, 2002; 11(1): 29 - 34. [Abstract] [Full Text]

				G D Loizou and J Cocker The effects of alcohol and diallyl sulphide on CYP2E1 activity in humans: a phenotyping study using chlorzoxazone Human and Experimental Toxicology, July 1, 2001; 20(7): 321 - 327. [Abstract] [PDF]

				W. Tan, N. Song, G.-Q. Wang, Q. Liu, H.-J. Tang, F. F. Kadlubar, and D.-X. Lin Impact of Genetic Polymorphisms in Cytochrome P450 2E1 and Glutathione S-Transferases M1, T1, and P1 on Susceptibility to Esophageal Cancer among High-Risk Individuals in China Cancer Epidemiol. Biomarkers Prev., June 1, 2000; 9(6): 551 - 556. [Abstract] [Full Text]

				T. Shimada, F. Tsumura, and H. Yamazaki Prediction of Human Liver Microsomal Oxidations of 7-Ethoxycoumarin and Chlorzoxazone with Kinetic Parameters of Recombinant Cytochrome P-450 Enzymes Drug Metab. Dispos., November 1, 1999; 27(11): 1274 - 1280. [Abstract] [Full Text]

				L. L. Marchand, G. R. Wilkinson, and L. R. Wilkens Genetic and Dietary Predictors of CYP2E1 Activity: A Phenotyping Study in Hawaii Japanese Using Chlorzoxazone Cancer Epidemiol. Biomarkers Prev., June 1, 1999; 8(6): 495 - 500. [Abstract] [Full Text]

				J.-W. Ko, N. Sukhova, D. Thacker, P. Chen, and D. A. Flockhart Evaluation of Omeprazole and Lansoprazole as Inhibitors of Cytochrome P450 Isoforms Drug Metab. Dispos., July 1, 1997; 25(7): 853 - 862. [Abstract] [Full Text]